In pediatric low-grade gliomas, including OPGs, aberrations such as BRAF–KIAA1549 fusion and BRAF V600E mutation constitutively activate the MAPK pathway, driving uncontrolled tumor cell proliferation and contributing to treatment resistance. Here, BRAF is linked to glioma.